Sanofi Pasteur uses novel technology for development of a 2nd-gen influenza vaccine

Sanofi Pasteur announces published data on a vaccine strategy that elicited a broadly-reactive response against seasonal and pandemic H1N1 influenza viruses in mice. The article, entitled ‘Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses,’ appears in the current issue of the Journal of Virology. Sanofi Pasteur is presenting the data tomorrow, March 30, at the 2016 World Vaccine Congress being held in Washington, DC. —> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail